# JUPITER-02 (NCT03581786)

> The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

No report yet. It can be ordered.

- Drugs tested: toripalimab
- Indication: recurrent or metastatic nasopharyngeal carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03581786
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Conditions: Recurrent or Metastatic NPC
- Interventions: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy; Placebos
- Enrollment: 289
- Primary outcome: IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1

## Indexed commentary on JUPITER-02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 10 posts on X
- 7 YouTube videos
- 6 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=jupiter-02-nct03581786

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03581786", "email": "<work email>"}; the inbox owner confirms by the emailed link.